Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The PDUFA Negotiations: Modern Myth

This article was originally published in RPM Report

Executive Summary

Negotiation is supposed to be a two way street--one sides gives a bit, and so does the other side. When it comes to FDA/industry "negotiations" over user fees, that isn't the model at all. Let's call it what it is: a tax on industry, with Congress giving FDA what it wants.

You may also be interested in...



Specialty Drug Tier: When Special Means Expensive

Medicare led the way to create a policy that’s just plain mean. Is there any way back?

Pharma's Stake In Essential Health Benefits

The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.

What's Next for Broadcast DTC Advertising?

Defending DTC is one thing. But getting defensive about it is a big mistake.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel